$VIRX
Viracta Therapeutics, Inc.

2015 Q4 Form 10-K Financial Statement

#000156459016014612 Filed on March 14, 2016

View on sec.gov

Income Statement

Concept 2015 Q4 2014 Q4 2014 Q3
Revenue $670.0K $896.0K $854.0K
YoY Change -25.22% -54.95% -57.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.380M $6.080M $7.230M
YoY Change -27.96% 125.19% 157.3%
% of Gross Profit
Research & Development $7.630M $5.970M $6.939M
YoY Change 27.81% -13.23% -0.26%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $12.01M $12.05M $14.17M
YoY Change -0.33% 25.78% 45.07%
Operating Profit -$13.31M
YoY Change 71.2%
Interest Expense -$230.0K -$310.0K $391.0K
YoY Change -25.81% -50.0% -43.74%
% of Operating Profit
Other Income/Expense, Net $0.00 $10.14M -$1.623M
YoY Change -100.0% 875.0% -288.06%
Pretax Income -$11.58M -$1.320M -$15.33M
YoY Change 777.27% -81.62% 101.45%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$11.58M -$1.320M -$15.33M
YoY Change 777.27% -81.62% 101.46%
Net Earnings / Revenue -1728.36% -147.32% -1794.5%
Basic Earnings Per Share -$0.91 -$0.02 -$0.25
Diluted Earnings Per Share -$0.91 -$0.02 -$0.25
COMMON SHARES
Basic Shares Outstanding 12.78M 63.04M 60.55M
Diluted Shares Outstanding 12.78M 63.04M 60.55M

Balance Sheet

Concept 2015 Q4 2014 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.40M $43.00M $44.70M
YoY Change 7.91% 9.41% -1.76%
Cash & Equivalents $26.89M $22.19M $20.81M
Short-Term Investments $19.50M $20.80M $23.90M
Other Short-Term Assets $600.0K $1.200M $1.300M
YoY Change -50.0% 0.0% 30.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $46.99M $44.20M $46.00M
YoY Change 6.3% 9.17% -1.11%
LONG-TERM ASSETS
Property, Plant & Equipment $14.00K $42.00K $53.00K
YoY Change -66.67% 82.61% 96.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $14.00K $42.00K $53.00K
YoY Change -66.67% 27.27% 23.26%
TOTAL ASSETS
Total Short-Term Assets $46.99M $44.20M $46.00M
Total Long-Term Assets $14.00K $42.00K $53.00K
Total Assets $47.00M $44.25M $46.05M
YoY Change 6.23% 9.18% -1.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.453M $3.177M $772.0K
YoY Change -22.79% 233.37% -47.09%
Accrued Expenses $6.300M $8.500M $9.600M
YoY Change -25.88% 4.94% 18.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.800M $9.300M $9.900M
YoY Change -16.13% 3.33% 12.5%
Total Short-Term Liabilities $19.00M $27.88M $37.31M
YoY Change -31.86% -17.93% 5.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $1.700M
YoY Change -100.0% -84.96%
Other Long-Term Liabilities $600.0K $2.600M $3.400M
YoY Change -76.92% -29.73% -40.35%
Total Long-Term Liabilities $600.0K $2.600M $5.100M
YoY Change -76.92% -79.53% -70.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.00M $27.88M $37.31M
Total Long-Term Liabilities $600.0K $2.600M $5.100M
Total Liabilities $19.60M $30.40M $42.40M
YoY Change -35.53% -34.9% -18.93%
SHAREHOLDERS EQUITY
Retained Earnings -$522.7M -$521.4M
YoY Change 8.96% 10.34%
Common Stock $536.5M $525.0M
YoY Change 13.3% 12.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.39M $13.80M $3.615M
YoY Change
Total Liabilities & Shareholders Equity $47.00M $44.25M $46.05M
YoY Change 6.22% 9.18% -1.08%

Cashflow Statement

Concept 2015 Q4 2014 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income -$11.58M -$1.320M -$15.33M
YoY Change 777.27% -81.62% 101.46%
Depreciation, Depletion And Amortization $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$9.270M -$9.010M -$12.54M
YoY Change 2.89% -7.11% 44.3%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$30.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$5.850M $3.120M $7.860M
YoY Change -287.5% -793.33% -59.51%
Cash From Investing Activities -$5.850M $3.120M $7.850M
YoY Change -287.5% -793.33% -59.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $25.20M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.21M 7.270M -1.250M
YoY Change 246.77% 105.37% -128.34%
NET CHANGE
Cash From Operating Activities -9.270M -9.010M -12.54M
Cash From Investing Activities -5.850M 3.120M 7.850M
Cash From Financing Activities 25.21M 7.270M -1.250M
Net Change In Cash 10.09M 1.380M -5.940M
YoY Change 631.16% -120.88% -139.26%
FREE CASH FLOW
Cash From Operating Activities -$9.270M -$9.010M -$12.54M
Capital Expenditures $0.00 $0.00 -$30.00K
Free Cash Flow -$9.270M -$9.010M -$12.51M
YoY Change 2.89% -7.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2015Q4 us-gaap Notes Payable Current
NotesPayableCurrent
7834000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18999000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
16459000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-522697000
CY2015Q4 us-gaap Assets
Assets
47002000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1606000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2711000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2453000
CY2015Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
1954000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
20200
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2441000
CY2014Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3543000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2563000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
536499000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66102000
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66102000
CY2013 snss License And Other Revenue
LicenseAndOtherRevenue
7956000
CY2013 us-gaap Revenues
Revenues
7956000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28891000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10838000
CY2013 us-gaap Operating Expenses
OperatingExpenses
39729000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34639000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27881000
CY2013 us-gaap Interest Expense
InterestExpense
2917000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
92000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6149000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
13802000
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44246000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
610000
CY2013 snss Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
88000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-31773000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-34598000
CY2013 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
-41000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
11957000
CY2013 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
11986000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
230000
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
309000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3581000
CY2013 snss Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value For Non Employees
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValueForNonEmployees
304000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-6184000
CY2014 snss Adjustments To Additional Paid In Capital Common Stock And Warrant Issued
AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantIssued
40024000
CY2014 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
14292000
CY2014 snss Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
949000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1226000
CY2014 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
282000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5882000
CY2014 snss Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value For Non Employees
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValueForNonEmployees
337000
CY2015 snss Adjustments To Additional Paid In Capital Common Stock And Warrant Issued
AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantIssued
8709000
CY2015 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
18125000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
331000
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
202000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16459000
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
100000
CY2015 snss Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value For Non Employees
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValueForNonEmployees
196000
CY2013 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
12357000
CY2014 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
43013000
CY2015 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
9236000
CY2013 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
371000
CY2014 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
2989000
CY2015 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
527000
CY2014 snss Issuance Of Common Stock And Warrants In Underwritten Offering
IssuanceOfCommonStockAndWarrantsInUnderwrittenOffering
14734000
CY2015 snss Issuance Of Common Stock And Warrants In Underwritten Offering
IssuanceOfCommonStockAndWarrantsInUnderwrittenOffering
18564000
CY2014 snss Issuance Of Common Stock And Warrants In Underwritten Offering Issuance Costs
IssuanceOfCommonStockAndWarrantsInUnderwrittenOfferingIssuanceCosts
442000
CY2015 snss Issuance Of Common Stock And Warrants In Underwritten Offering Issuance Costs
IssuanceOfCommonStockAndWarrantsInUnderwrittenOfferingIssuanceCosts
439000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6345000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6219000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3885000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20000
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
135000
CY2014 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
367000
CY2013 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
621000
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3543000
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3892000
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-96000
CY2013 snss Exchange Gain Loss On Marketable Securities
ExchangeGainLossOnMarketableSecurities
142000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-660000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
43000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-489000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-724000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2224000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
875000
CY2015 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-1158000
CY2014 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-1638000
CY2013 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-699000
CY2015 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-681000
CY2014 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
568000
CY2013 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
254000
CY2015 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-186000
CY2014 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1674000
CY2013 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-76000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2930000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5687000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-7956000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-38731000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-43181000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-37423000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
35683000
CY2014 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
42463000
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
26894000
CY2015 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
36930000
CY2014 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
45836000
CY2013 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
59110000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1247000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
3325000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
32216000
CY2015 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1642000
CY2014 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
9356000
CY2013 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7182000
CY2015 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
16459000
CY2014 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
40024000
CY2015 snss Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
8709000
CY2015 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
18125000
CY2014 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
14292000
CY2013 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
11986000
CY2015 snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
533000
CY2014 snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
1961000
CY2013 snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
584000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
42184000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
46921000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5388000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4700000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7065000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
181000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15121000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14940000
CY2015 us-gaap Interest Paid
InterestPaid
631000
CY2014 us-gaap Interest Paid
InterestPaid
1221000
CY2013 us-gaap Interest Paid
InterestPaid
2006000
CY2015 snss Transfer Of Fair Value Of Exercised Warrants To Additional Paid In Capital
TransferOfFairValueOfExercisedWarrantsToAdditionalPaidInCapital
100000
CY2014 snss Transfer Of Fair Value Of Exercised Warrants To Additional Paid In Capital
TransferOfFairValueOfExercisedWarrantsToAdditionalPaidInCapital
496000
CY2013 snss Transfer Of Fair Value Of Exercised Warrants To Additional Paid In Capital
TransferOfFairValueOfExercisedWarrantsToAdditionalPaidInCapital
43000
CY2015 us-gaap Stock Issued1
StockIssued1
4486000
CY2014 us-gaap Stock Issued1
StockIssued1
9337000
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to the valuation of equity and related instruments, revenue recognition, stock-based compensation and clinical trial accounting.</p></div>
CY2014 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
19803000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
30334000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
30327000
CY2014Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9532000
CY2014Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
20802000
CY2014Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
7000
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
9532000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
11000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
11649000
CY2015 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2014 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2013 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1998-02-10
CY2015Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
46400000
CY2015 snss Securities Policy Maturity Limit Period
SecuritiesPolicyMaturityLimitPeriod
P24M
CY2015 snss Securities Policy Dollar Weighted Average Maturity Limit Period
SecuritiesPolicyDollarWeightedAverageMaturityLimitPeriod
P12M
CY2015 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2015Q4 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
700000
CY2014Q4 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
0
CY2010Q4 snss Proceeds From Issuance Of Common Shares And Warrants In Offering Gross
ProceedsFromIssuanceOfCommonSharesAndWarrantsInOfferingGross
15500000
CY2015 snss Measurement Dates Of Fair Market Value For Employee Stock Purchase Plan Purchases
MeasurementDatesOfFairMarketValueForEmployeeStockPurchasePlanPurchases
At the beginning of a 12-month offering period or at the end of one of the two related six-month purchase periods.
CY2014 snss Fair Value Adjustment Of Warrant Liabilities
FairValueAdjustmentOfWarrantLiabilities
3892000
CY2014 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1453000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38747000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19562000
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17589000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
39358000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
39347000
CY2015Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
19803000
CY2015Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
19555000
CY2015Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
11000
CY2015Q4 snss Common Stock Fair Value
CommonStockFairValue
0.00
CY2014Q4 snss Common Stock Fair Value
CommonStockFairValue
2.55
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.52
CY2015 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P0Y
CY2014 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P9M18D
CY2015 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.000
CY2014 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.449
CY2015 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.000
CY2014 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.002
CY2015 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2014Q4 snss Accrued Outside Service Fees Current
AccruedOutsideServiceFeesCurrent
2656000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
644000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
355000
CY2015Q4 snss Other Accruals Current
OtherAccrualsCurrent
56000
CY2014Q4 snss Other Accruals Current
OtherAccrualsCurrent
76000
CY2015Q3 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
600000
CY2015Q2 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
900000
CY2015 us-gaap Dividends Share Based Compensation Cash
DividendsShareBasedCompensationCash
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10584000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3291000
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
170000
CY2014Q4 snss Warrants Estimated Fair Value Per Warrant Share
WarrantsEstimatedFairValuePerWarrantShare
1.21
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2920000
CY2015Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2015Q4 snss Accrued Outside Service Fees Current
AccruedOutsideServiceFeesCurrent
2011000
CY2015Q4 snss Revenue Participation Right Payment Rate
RevenueParticipationRightPaymentRate
0.0675
CY2015 snss Revenue Participation Right Payment Term
RevenueParticipationRightPaymentTerm
10 years from the date of first commercial sale
CY2015 snss Maximum Term Of Revenue Participation Right Payments
MaximumTermOfRevenueParticipationRightPayments
P10Y
CY2015Q4 us-gaap Notes Payable
NotesPayable
7834000
CY2015 snss Operating Lease Agreement Amended Date
OperatingLeaseAgreementAmendedDate
2014-09
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
277000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
277000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015 us-gaap Common Stock Voting Rights
CommonStockVotingRights
One vote per share
CY2014Q1 snss Proceeds From Issuance Of Common Shares And Warrants In Offering Gross
ProceedsFromIssuanceOfCommonSharesAndWarrantsInOfferingGross
43000000
CY2014Q1 snss Proceeds From Issuance Of Common Shares And Warrants In Offering Net
ProceedsFromIssuanceOfCommonSharesAndWarrantsInOfferingNet
40000000
CY2015Q4 snss Proceeds From Issuance Of Common Stock Gross
ProceedsFromIssuanceOfCommonStockGross
26200000
CY2015Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25200000
CY2015Q4 snss Fair Value Of Shares Issuable Under Employee Stock Purchase Plan
FairValueOfSharesIssuableUnderEmployeeStockPurchasePlan
25000
CY2015 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
130491000
CY2015Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5628000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1384000
CY2015Q4 snss Share Based Compensation Arrangement Outstanding Securities
ShareBasedCompensationArrangementOutstandingSecurities
18547000
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19931000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5800000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2600000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3400000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1209000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12496000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11824000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
7385000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.93
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.40
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.95
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.33
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.05
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.05
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.47
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M5D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y6M22D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M22D
CY2014 snss Income Tax Reconciliation Other Permanent Differences
IncomeTaxReconciliationOtherPermanentDifferences
259000
CY2013 snss Income Tax Reconciliation Other Permanent Differences
IncomeTaxReconciliationOtherPermanentDifferences
529000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
147408000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
138066000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12557000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
5000
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2700000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2015 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8000000
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-23705000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-32696000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-29963000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-12971000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-10306000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4635000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36676000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43002000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34598000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2015Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-12470000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-14620000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11763000
CY2015 snss Income Tax Reconciliation Net Operating Loss And Temporary Differences
IncomeTaxReconciliationNetOperatingLossAndTemporaryDifferences
9596000
CY2014 snss Income Tax Reconciliation Net Operating Loss And Temporary Differences
IncomeTaxReconciliationNetOperatingLossAndTemporaryDifferences
14104000
CY2013 snss Income Tax Reconciliation Net Operating Loss And Temporary Differences
IncomeTaxReconciliationNetOperatingLossAndTemporaryDifferences
12457000
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
4410000
CY2014 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
3504000
CY2013 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1499000
CY2015 snss Income Tax Reconciliation Deferred Revenue
IncomeTaxReconciliationDeferredRevenue
996000
CY2014 snss Income Tax Reconciliation Deferred Revenue
IncomeTaxReconciliationDeferredRevenue
1934000
CY2013 snss Income Tax Reconciliation Deferred Revenue
IncomeTaxReconciliationDeferredRevenue
2706000
CY2015 snss Income Tax Reconciliation Change In Fair Value Of Warrant Liability
IncomeTaxReconciliationChangeInFairValueOfWarrantLiability
-1204000
CY2014 snss Income Tax Reconciliation Change In Fair Value Of Warrant Liability
IncomeTaxReconciliationChangeInFairValueOfWarrantLiability
-1313000
CY2013 snss Income Tax Reconciliation Change In Fair Value Of Warrant Liability
IncomeTaxReconciliationChangeInFairValueOfWarrantLiability
-16000
CY2015 snss Income Tax Reconciliation Other Permanent Differences
IncomeTaxReconciliationOtherPermanentDifferences
664000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12964000
CY2015Q4 snss Deferred Tax Assets Capitalized Research Cost
DeferredTaxAssetsCapitalizedResearchCost
5119000
CY2014Q4 snss Deferred Tax Assets Capitalized Research Cost
DeferredTaxAssetsCapitalizedResearchCost
5199000
CY2015Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1221000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2394000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5275000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4358000
CY2015Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
127000
CY2014Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
129000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
133000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
481000
CY2015Q1 us-gaap Revenues
Revenues
854000
CY2015Q2 us-gaap Revenues
Revenues
854000
CY2015Q3 us-gaap Revenues
Revenues
683000
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9128000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8949000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7021000
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9128000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10816000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7021000
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67641000
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72513000
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74776000
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67641000
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72525000
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74776000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
171840000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
163591000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
171840000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
163591000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1285000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
96000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1381000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8400000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14600000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12600000
CY2015Q4 snss Indemnification Liabilities Incurred
IndemnificationLiabilitiesIncurred
0
CY2015Q4 us-gaap Revenues
Revenues
670000
CY2014Q1 us-gaap Revenues
Revenues
1995000
CY2014Q2 us-gaap Revenues
Revenues
1989000
CY2014Q3 us-gaap Revenues
Revenues
854000
CY2014Q4 us-gaap Revenues
Revenues
896000
CY2015Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11578000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14573000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11781000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15325000
CY2014Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1323000
CY2015Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11578000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14573000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12114000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15325000
CY2014Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1323000
CY2015Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76683000
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56313000
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60246000
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60549000
CY2014Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63041000
CY2015Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76683000
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56313000
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61895000
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60549000
CY2014Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63041000
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02

Files In Submission

Name View Source Status
0001564590-16-014612-index-headers.html Edgar Link pending
0001564590-16-014612-index.html Edgar Link pending
0001564590-16-014612.txt Edgar Link pending
0001564590-16-014612-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2016031122260099911570.jpg Edgar Link pending
g2016031122261069611571.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10k_20151231.htm Edgar Link pending
snss-20151231.xml Edgar Link completed
snss-20151231.xsd Edgar Link pending
snss-20151231_cal.xml Edgar Link unprocessable
snss-20151231_def.xml Edgar Link unprocessable
snss-20151231_lab.xml Edgar Link unprocessable
snss-20151231_pre.xml Edgar Link unprocessable
snss-ex1045_501.htm Edgar Link pending
snss-ex231_588.htm Edgar Link pending
snss-ex311_376.htm Edgar Link pending
snss-ex312_375.htm Edgar Link pending
snss-ex321_377.htm Edgar Link pending